FDA approves Tonix’ Phase 2 Trial of TNX-2900 for Prader-Willi SyndromeThe FDA has cleared Tonix Pharmaceuticals’ Investigational New Drug (IND) application to support clinical development of TNX-2900...
Multisociety clinical practice guidance says most patients can continue GLP-1 anti-obesity drugs before surgery8 hours ago